CTLA4: A Protein Implicated in Tumor Immune Evasion and Treatment

Target Name: CTLA4

NCBI ID: G1493

CTLA4

CTLA4: A Protein Implicated in Tumor Immune Evasion and Treatment

CTLA4 (CD152) is a protein that is expressed in various tissues throughout the body, including the skin, lungs, and gastrointestinal tract. It is a member of the immune globulin superfamily and belongs to the CD152 family. Studies have shown that CTLA4 is expressed in a variety of tumors, including lung cancer, breast cancer, lymphoma, etc. In addition, CTLA4 is associated with a variety of autoimmune diseases and transplant rejection.

As an immune checkpoint molecule, CTLA4 plays an important role in tumor immune evasion. Tumor cells can suppress immune system responses, thereby evading immune surveillance and attack. As an immune checkpoint molecule, CTLA4 can activate T cells and promote the killing effect of immune cells on tumor cells.

In addition, CTLA4 is also related to the response of PD-1 positive T cells. PD-1 positive T cells are one of the important ways of T cell immune escape. CTLA4 can bind to PD-1 molecules on PD-1 positive T cells, thereby inhibiting their immune evasion ability.

CTLA4 is also associated with tumor cell growth and invasion. Studies have shown that the expression level of CTLA4 is positively correlated with the invasive ability of tumor cells. In addition, CTLA4 can also affect the growth and metastasis of tumor cells.

As a biomarker, CTLA4 can be used to predict the survival of cancer patients. By detecting the expression level of CTLA4, the survival time of tumor patients can be predicted. In addition, CTLA4 can also be used as a target for tumor immunotherapy to promote the killing effect of immune cells on tumor cells.

As an immune checkpoint molecule, CTLA4 is of great significance in tumor immune evasion and treatment. With the continuous development of science and technology, researchers will continue to study the role of CTLA4 in tumor immune escape and search for new treatment methods and targets.

Protein Name: Cytotoxic T-lymphocyte Associated Protein 4

Functions: Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28

The "CTLA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTLA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets